Loading clinical trials...
Loading clinical trials...
A Phase 1/1b Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 436 as Monotherapy and in Combination With Other Therapies in Participants With Microsatellite Instability-high (MSI-H)/Mismatch Repair Deficient (dMMR) Solid Tumors
Conditions
Interventions
AMG 436
Locations
6
United States
Next Oncology - Dallas
Irving, Texas, United States
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China
Aichi Cancer Center
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Koto-ku, Tokyo, Japan
Start Date
April 8, 2026
Primary Completion Date
June 28, 2028
Completion Date
June 28, 2028
Last Updated
April 20, 2026
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions